NCT05455294 - Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Myeloid MalignancyMyelodysplastic SyndromesMyelofibrosisAcute Myeloid LeukemiaMyeloproliferative Neoplasm

Interventions

DRUG

Navitoclax

See Arm Description

DRUG

Venetoclax

See Arm Description

DRUG

Decitabine

See Arm Description

Trial Locations (3)

Brigham and Women's Hospital, Boston

Dana Farber Cancer Institute, Boston

Beth Israel Deaconess Medical Center, Boston